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ABSTRACT
Objective. A review of the evidence supporting the use of
radiotherapy in patients with mesothelioma was per-
formed.
Methods. Relevant publications were searched for on
Medline.
Results. In a Medline search on radiotherapy and me-
sothelioma, 611 hits were obtained. A limited number of
prospective phase II trials of radiotherapy as part of tri-
modality protocols for early disease and in the palliation
of pain were found, along with three small randomized
controlled trials of port-site prophylaxis.
Conclusion. No randomized data exist to support the
use of radiotherapy after radical surgery, although there
are a large number of publications describing its use as an
integral part of therapy, including seven phase II studies.
One ongoing trial is randomizing patients to radiotherapy
or not after extrapleural pneumonectomy. None of these
studies provided any assessment of radiotherapy indepen-
dent of the other modalities investigated, nor did any for-
mally assess intensity-modulated radiotherapy. There
have been several reports of excessive toxicity with this
technique, and its use should be limited to phase I studies
until the basis of this toxicity is better understood. Three
trials have looked at port-site prophylaxis, one supporting
its use and two showing no evidence of benefit. Two studies
addressed pain control prospectively, one showing definite
but short-lived benefits.
Implications. Radiotherapy is widely used in treating
mesothelioma with little supporting evidence. More
randomized trials are required to justify this use in all
three common settings for its use. The Oncologist 2011;
16:359–365
INTRODUCTION
Radiotherapy is widely used in the treatment of patients with
mesothelioma, as an integral part of trimodality therapy for
early stage disease, in the prophylaxis of port-site recurrence
and in the palliation of pain. The purpose of this review is to
identify the published evidence on which this practice is based,
to identify gaps in the evidence which could be filled, and in-
dicate those areas where current practice appears to fly in the
face of existing published evidence.
METHODS
A Medline search using the terms radiotherapy and mesothe-
lioma was performed, producing 611 hits. Those available in
the English literature, and referring to clinical practice, were
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identified and form the basis of this review. No detailed anal-
ysis of the literature relating to technical aspects of radiother-
apy has been attempted, although these issues will be alluded
to when relevant. The review is divided into three sections re-
ferring to the different areas of practice described above.
RESULTS
Radiotherapy As a Component of
Radical Treatment
Trimodality therapy with curative intent has been at-
tempted, and described in small series, for over 30 years.
An early report of eight patients treated with surgery, radio-
therapy, and doxorubicin-containing chemotherapy found
no patient relapse-free beyond 2 years [1]. At Memorial
Sloan-Kettering, pleurectomy was supplemented with in-
trapleural implantation with I125 and P32 and adjuvant ex-
ternal beam radiotherapy to 45 Gy, but with 2-year disease-
free survival of only 13% [2]. Radiological and clinical
deterioration in lung function after high-dose radiotherapy
was also reported at an early stage in these series. Maasilta
[3] observed almost complete radiological opacification of
the hemithorax a year after radiotherapy, with reduced lung
volumes and diffusion capacity and hypoxia in one third of
patients. These same authors observed no difference in out-
comes to a range of radiotherapy schedules extending from
20 Gy in 10 daily fractions to 70 Gy in 56 fractions over 7
weeks. Only 2 of 57 patients were alive at 6 and 9 years [4].
Extrapleural Pneumonectomy and
Adjuvant Radiotherapy
The era of widespread research interest in extrapleural
pneumonectomy (EPP) for pleural mesothelioma was her-
alded by Sugarbaker et al.’s report [5] of 22% 5-year sur-
vival in 120 patients whose tumors were resected over a 15-
year period. Postoperative radiotherapy was part of the
protocol described and has remained so in almost all subse-
quent studies, although one of the best reported outcomes
was in patients who did not receive radiotherapy [6]. No
randomized data have been produced to support a role for
adjuvant radiotherapy, but an increase in dose to 54 Gy in
New York was associated with a reduction in local failure to
7 of 62 (11%) [7] compared to the 35% of 49 patients pre-
viously reported in Boston [8]. A subsequent report from
Boston comparing 25 patients treated between 1994 and
2002 with 30 Gy to the hemithorax, 40 Gy to the mediasti-
num, and 54 Gy to original sites of disease with 14 patients
treated in 2003 and 2004 to 54 Gy to the hemithorax found
no dose effect [9].
Intensity Modulated Radiotherapy
Further attempts at improving local control with radiother-
apy after EPP have focused on intensity modulated radio-
therapy (IMRT), initially in the curative setting at MD
Anderson [10, 11] and in the palliative setting in Heidelberg
[12]. See Table 1. In the initial report of the former, local
control at 13 months with minimal toxicity was reported in
7 patients; in the latter, median survival was 6.5 months
from radiotherapy. The MD Anderson series was later up-
dated to 63 irradiated patients of 100 who originally under-
went EPP, the remainder having died (11), progressed (15),
become unfit (9), or refused (2). In-field recurrence oc-
curred in 3, locoregional failure in 8, but systemic failure in
33 [14]. However, early mortality was significant with 23
deaths within 6 months, including 10 from recurrence, 4
from pneumonia, 2 from pneumonitis, 2 from pulmonary
embolism, and 1 from a bronchopleural fistula, with the
volume of lung receiving 20 Gy or greater (V20), predicting
increased treatment-related mortality. These data rein-
forced the experience in Boston where 6 of 13 patients
treated with IMRT died from radiation pneumonitis after
receiving a prescribed dose of 54 Gy in 30 daily fractions
with lung V20 20% [15]. The authors suggested this was
related to higher radiation doses in the single lung after ex-
trapleural pneumonectomy, although the possibility of un-
derlying undiagnosed asbestos-related interstitial lung
disease was not explored. Other retrospective series have
also reported outcomes with IMRT following EPP. Budu-
han and colleagues [16] reported a 14% local recurrence
rate in 14 patients treated with IMRT compared with 42% in
24 patients receiving conventional radiotherapy. They re-
ported no treatment-related deaths with a prescribed dose of
50.4 Gy in 30 daily fractions and median lung V20 of 7%.
Kristensen et al. [17] reported 4 deaths from radiation pneu-
monitis in 26 patients receiving chemotherapy, EPP, and
IMRT with a prescribed dose of 50 Gy in 30 daily fractions
and median lung V20 of 14%. The group who developed
pneumonitis had a significantly higher mean volume of
Table 1. Published series of IMRT following EPP
Study
No.
entered
No. alive and
disease-free
Early
nonmesothelioma
mortality
MD Anderson 13 63 8 @ 35 mo(s) 7
Brigham 15 13 3 @16 mo(s) 6
Swedish C.I 16 14 Not reported 0
Rigshospitalet 17 26 Not reported 5
Miles 18 13 6 @ 9 mo(s) 1
Abbreviations: EPP, extrapleural pneumonectomy;
IMRT, intensity modulated radiotherapy.
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lung receiving 10 Gy or greater (V10), but there was a sub-
stantial overlap of individual values. Miles et al. [18] re-
ported 13 patients treated between 2005 and 2007 at Duke
University with IMRT to a median dose of 45 Gy after EPP.
One patient died from radiation pneumonitis with a lung
V20 of 7% and volume of lung receiving 5 Gy or greater
(V5) of 92%. Six patients had relapsed and 6 were alive and
disease-free with median follow-up of 9.5 months.
Several planning studies have suggested IMRT reduced
dose to organs at risk such as liver, heart, and kidneys [19]
and lung [20], although the latter seemed to conflict with
the clinical data. However, other studies suggested that con-
ventional techniques gave lower doses to the contralateral
lung, heart, and contralateral kidney, with little effect on
target, ipsilateral kidney, spine, or liver [21, 22]. Moreover,
it has been suggested that commercial planning systems
might underestimate the dose in areas outside the target vol-
ume where the absorbed dose was less than half the pre-
scribed dose [23]. Following the toxicities reported above,
the Boston group has attempted to make their constraints
for beam distribution and prescribed dose more rigorous,
producing superior plans to those used previously but with-
out any supporting clinical data yet to show reduced toxic-
ity [24]. Currently, it must be concluded there is no
evidence for benefit from IMRT after EPP, and its use must
be considered experimental in carefully monitored phase I
studies. The reasons why some patients are more sensitive
to this form of treatment are unclear, and planning param-
eters do not clearly divide those at increased risk of death
because of radiotherapy from those who are not at such risk.
Prospective Studies of Trimodality Therapy
No randomized data exist yet looking at post-EPP radio-
therapy, although a Swiss trial is expected to reach comple-
tion in 2011. No formal prospective protocol (i.e., with a
phase II design with specified hypothesis) has featured
IMRT, but 7 prospective studies of trimodality therapy with
conventional radiotherapy have been reported [25–31] in-
volving 313 patients (Table 2). The Memorial Sloan-Ket-
tering series [25] was in patients with inoperable stage
III-IV disease, with a primary endpoint of 20% response to
chemotherapy, which was achieved (26%). Three patients
were alive and disease-free at time of report. The study re-
ported by Krug et al. [31] was powered to find a 7% path-
ological complete response rate at EPP; this was not
achieved, the rate in the intention-to-treat population being
4%. The EORTC trial [30] also failed to achieve its primary
endpoint, the proportion of patients alive and disease-free
and with residual toxicities grade 2 or less 3 months off pro-
tocol treatments. The target was 50%, but it was achieved in
only 41%. The Swiss trial [28] was designed to find a 20%
reduction in psychological distress between baseline and 3
months after surgery, which under normal circumstances
would have been mid-radiotherapy. No change in rates of
distress was seen. In all but one study, median survival was
between 16 and 20 months, but almost half of patients failed
to complete all planned therapies. A further study, of which
the results have not yet been presented, has examined the
feasibility of carrying out a phase III trial comparing trimo-
dality therapy and chemotherapy alone. Of 112 patients
who were thought operable at presentation and commenced
chemotherapy, 50 were ultimately randomized to EPP plus
radiotherapy or further nonsurgical management [32].
Current evidence suggests that a small group of patients
thought operable, who are found at surgery to have early
stage, node negative, epithelioid disease and achieve com-
plete resection, have an expectation of prolonged survival,
but because they cannot be identified preoperatively, a
larger group of patients with very little chance of long-term
survival must also undergo this aggressive treatment with
its high morbidity and measurable mortality. Moreover, it
remains unclear what chemotherapy or radiotherapy adds to
the surgery, and what IMRT may add to the risks of treat-
ment, again with no evidence that it produces any benefit.
Table 2. Prospective studies of trimodality therapy including extrapleural pneumonectomy
Study No. entered
No. completing
all therapy
Median
survival [mo(s)]
Protocol-related
deaths
Umberto I, Venice 25 54 32 20 2
Memorial Sloan-Kettering, New York 26 21 8 19 0
Padua 27 21 15 25.5 0
SAKK 28 61 36 19.8 1
Marmara, Istanbul 29 20 12 16 1
U.S. multicenter 31 77 40 16.8 3
EORTC 30 59 37 18.3 5
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Pleurectomy/Decortication and Adjuvant Radiotherapy
Disappointment at the relative failure of EPP has led many
centers back to pleurectomy/decortication (P/D) plus adju-
vant chemotherapy and radiotherapy. No data on quality of
life changes consequent upon this therapy are available. A
series of 123 patients treated at Memorial Sloan-Kettering
between 1974 and 2003 reported 13-month median survival
and only two protocol-related deaths [33]. In a series of 32
patients treated in San Francisco between 1995 and 2000,
median survival was 18 months, although median fol-
low-up was only 9 months [34]. In a phase II study of 49
patients receiving four-modality therapy including immu-
notherapy, median survival was 26 months [35]. Luckraz et
al. [36] also reported 26-month median survival in 24 pa-
tients treated by P/D, chemotherapy, and radiotherapy, of
217 patients assessed. In this series this produced better out-
comes than achieved in patients selected for EPP in the
same center over the same period. It is to be hoped that fu-
ture surgical studies will at least compare P/D with EPP, al-
though many centers are likely to abandon EPP given the
high mortality and morbidity and small number of long-
term survivors. Any such studies should randomize the ra-
diotherapy component rather than simply assume a benefit
and include it automatically.
Radiotherapy for Port-Site Prophylaxis
The use of radiotherapy in this setting was first described in
20 patients who had 38 port-sites irradiated without any re-
currences [37]. A subsequent French trial appeared to con-
firm this, with 0 of 20 recurrences in 20 treated sites after 21
Gy in 3 daily fractions and 8 recurrences in 20 unirradiated
sites [38], but 2 more recent randomized trials [39, 40]
found no benefit of radiotherapy, in the context of a much
lower relapse rate in the range 10%–15% without radiother-
apy, in line with other recent studies (Table 3) [41]. One of
these studies could be criticized for its use of a single frac-
tion of relatively low energy electrons which might have
underdosed the pleural target in some patients. Only the last
trial occurred in the era of routine chemotherapy with pem-
etrexed-based combinations. A survey in The Netherlands
and Belgium [42] found that 32 of 38 (84%) of centers were
sufficiently swayed by this evidence to offer prophylactic
port-site radiotherapy, whereas in the United Kingdom
75% of centers used this treatment [43]. Occasional small
retrospective series continue to be published [44, 45] but to
date attempts to design randomized trials large enough to
answer this question definitively have not been funded. Ac-
cordingly, many thousands of fractions of radiotherapy
continue to be given annually with unconvincing support-
ing evidence, and despite the lack of any evidence that this
is regarded by patients as a significant problem, and the
likelihood that it is only one event in the general progres-
sion of the disease, with its prevention having no effect on
the survival of patients or the natural history of the disease.
Radiotherapy for Palliation of Symptoms
Most publications in this area are retrospective descriptions
of single center practice, with only two prospective trials.
Gordon et al. [1] reported 29 courses in 19 patients, for dys-
pnea, dysphagia, superior vena cava obstruction, and brain
metastases, with substantial palliation in 5 of 29 patients
correlating with radiotherapy doses of 40 Gy. A series
from Melbourne [46] reported that 65% of 26 courses of
palliative radiotherapy were “at least partly successful.” In
a subsequent update they described some symptomatic re-
lief in over half of patients without evidence of dose re-
sponse [47]. The first prospective assessment of the role of
radiotherapy in palliation was performed in Glasgow in the
1980s [48]. Twenty-two patients received 30 Gy in 10 frac-
tions to the whole hemithorax for pain; 13 had less pain at 1
month, but this had fallen to 3 by 3 months and 1 by 5
months. Median survival was only 4 months. In a second
study in Sweden [49], 47 patients received 40 Gy in 20 frac-
tions to the hemithorax; 16 subsequently received doxoru-
bicin and cyclophosphamide. Only 1 of 31 (3%) exhibited a
partial response, and the authors reported no favorable ef-
fect on chest pain, weight loss, and performance status.
Senan and colleagues reviewed the results of 227 radiother-
apy courses in 189 patients during a 17-year period; re-
sponse was slightly more common with fractions of 4 Gy or
greater with a median time to recurrence of pain of 2 months
[50].
Table 3. Randomized trials of port-site prophylaxis
Study No. entered
Radiotherapy dose
(Gy/fractions)
Port-site failure without
radiotherapy (%)
Port-site failure with
radiotherapy (%)
Marseille 38 40 21/3 20 0
Perth 39 58 10/1 10 7
Beatson 40 56 21/3 12 13
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DISCUSSION
A previous review of radiotherapy in mesothlioma con-
cluded “there is limited evidence for the role of radiother-
apy in the management of patients with MPM. Future
studies including radiotherapy for the treatment of such pa-
tients should include formal measures of quality of life and
symptom control” [51]. Nothing has happened since that
was written to alter the conclusion. Much work has gone
into exploring methods of radical treatment in the few
thought suitable for this treatment, again without any evi-
dence that such treatment is of any value, and very little into
the palliation of symptoms for what remains an incurable
disease in all who present with it.
Extensive phase II data has shown little evidence of a
treatment effect with trimodality therapy, and phase III tri-
als may not follow, because the size of trial required to
show an effect is likely to be prohibitive. Most phase II
studies suggest a very small cohort of long-term survivors,
but this may be a reflection of indolent biology rather than
efficacy of treatment, and no predictive factor that identi-
fies these patients has yet been found. Attempts at improv-
ing the results of radiotherapy by increasing treatment
complexity have if anything had the reverse effect. The
available evidence suggests IMRT should not be used after
EPP except under strict trial protocols, and even then as a
phase I procedure to establish what the safe levels of dose
are to contralateral lung and other organs at risk. It may be-
come clearer in 2011 when the ongoing SAKK trial is ana-
lyzed whether radiotherapy has any role after EPP, but if
phase III trials are opened to examine the value of EPP, fur-
ther questions regarding the role of adjuvant therapy should
be included, with some patients randomized to no radio-
therapy (and no chemotherapy). It is likely that some cen-
ters will continue to offer chemotherapy, EPP and
radiotherapy as a treatment package and it is to be hoped
that they will enroll their patients in biological studies to in-
vestigate predictive factors.
The role of radiotherapy after P/D is equally unclear.
Because this is by definition a palliative procedure, quality
of life data are urgently needed to justify the continued en-
thusiasm for it, and any radiotherapy included in P/D pro-
tocols should be subject to randomization. In the meantime,
there does not seem to be any justification for radiotherapy
outside such protocols given the lack of any evidence of
benefit and the significant possibility of harm.
As with early stage disease, the available evidence does
not support a role for radiotherapy in port-site prophylaxis,
and its role should be regarded as experimental. Whether
the frequency of port-site recurrences and the symptoms
that they cause justify adjuvant therapy is itself a matter for
debate, but if its use is to continue, rather than simply be
abandoned as a waste of time, it should be subjected to ran-
domized trials that include quality of life and economic
endpoints.
Perhaps the most promising role for radiotherapy is in
the palliation of pain. In patients with end-stage disease
with pain resistant to opiates, steroids, anticonvulsants, an-
aesthetic agents, and nonsteroidal anti-inflammatory
agents, palliative radiotherapy may improve pain control,
with the duration of pain control indicated by the available
data sufficient to last most of the remaining life of these pa-
tients. The very wide fields required may cause significant
fatigue, and again if a role is thought to exist for radiother-
apy in this setting, prospective studies showing improved
pain control and tolerable side effects are required. The ap-
plicability of the available prospective data to the modern
era of aggressive palliative medicine is questionable, but
the data do suggest a potential role that warrants investiga-
tion.
SUMMARY
There is currently no evidence to support the routine role of
radiotherapy in patients with mesothelioma. Its role in early
stage disease as a surgical adjuvant will depend on the pre-
vailing surgical fashion, but evidence of efficacy after ei-
ther EPP or P/D is required if it is to remain part of ongoing
protocols. Its role in port-site prophylaxis has been cast into
doubt by recent randomized trials, and this use should be
discontinued until evidence of benefit is shown in larger tri-
als in the chemotherapy era. There may be a role in the man-
agement of poorly controlled pain, but again prospective
evidence of benefit with modern treatments should be
sought.
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